Abstract
American Diabetes Association (ADA) has announced the new version of the standards of Medical Care in Diabetes-2021. The guideline of the diabetic patients with Older Adults seems to be used for a wide range of clinical practice. Among them, several impressive comments were found, where “Once-daily basal insulin injection therapy is associated with minimal side effects and maybe a reasonable option in many elder patients”. Recent topic includes Dual Action of Liraglutide and insulin degludec (DUAL) studies, and Xultophy has shown beneficial efficacy. Consequently, the trend would be developed from multiple daily injection (MDI) method to once daily injection.
Highlights
Diabetes has been highly prevalent for the elderly population
Diabetic condition has a close relationship with geriatric syndromes, including cognitive impairment, depression, persistent pain, falls, urinary incontinence, and polypharmacy
“Once-daily basal insulin injection therapy is associated with minimal side effects and maybe a reasonable option in many older patients“
Summary
Keywords American Diabetes Association (ADA), Dual Action of Liraglutide and Insulin Degludec (DUAL) studies, Xultophy, Multiple Daily Injection (MDI), Once Daily Injection In the actual medical practice, many elderly diabetic patients have been increased and treated [2]. The usual medical management for elder diabetic patients requires an adequate assessment of medical, functional, psychological, and social aspects, which means biopsycho-social domains [3]. The crucial points of pharmacological therapy recommendations include i) select oral hypoglycemic agents (OHA) with low risk of hypoglycemia, ii) avoid overtreatment common in elder diabetic adults [9], iii) make simplification of complex regimens [10], iv) consider necessary costs of care and insurance coverage for developing therapeutic plans.
Published Version (Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have